Notes: May 15, 2023 -- Adamis Pharmaceuticals Corporation (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Restated Certificate of Incorporation (the “Restated Certificate”) with the Secretary of State of Delaware, effective 12:01 a.m. Eastern time, to effect a 1-for-70 reverse stock split of the outstanding shares of the Company’s common stock, par value $0.0001 per share The Common Stock will begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market on May 22, 2023. The trading symbol for the Common Stock will remain “ADMP.” The new CUSIP number for the Common Stock following the Reverse Stock Split is 00547W307. <p> December 2013 -- As stated in the SEC filings, Adamis Pharmaceuticals Corp (OTCMKTS:ADMP) is an emerging pharmaceutical company who wants to get back to listing on the NASDAQ but they are still unable to get through all the trials and tests which means that the revenues section of their financial reports remains empty. At the same time, the losses are piling up and the accumulated deficit as of September 30 amounts to no less than $39 million. On August 1, an agreement was signed with 3M Co (NYSE:MMM). As a part of the deal, ADMP acquired an exclusive license for MMM's Taper Dry Powder technology which is currently under development and will be used for the treatment of asthma. ADMP paid $3 million for the license and if they pay a further $7 million, they will be able to acquire all the assets related to MMM's clever inhalers. A potential acquisition of the technology will give ADMP a huge boost, but unfortunately, the SEC filings show that the company simply doesn't have enough money to pay for it. On November 20, ADMP announced that they are proposing a public offering for a total of $25 million. The transaction will include common shares as well as warrants and the proceeds will be used to pay for the acquisition of technology from MMM, for the covering of some convertible notes, and for working capital purposes. The offering will help with the balance sheet, but there's another development which should have an even greater effect on investors' attitude towards ADMP. The management team want to effectuate a reverse stock split and apply for listing on NASDAQ. The ticker was deleted from the national exchange in 2005 (the company name back then was Cellegy Pharmaceuticals, Inc.). Listing on Nasdaq is expected on 12/13/2013 pending offering.